-
Mashup Score: 16
Poster presentation scheduled for June 1, 2024, 1:30-4:30 PM CT /2:30-5:30 PM ET Trial being led by Georgetown University’s Lombardi Comprehensive Cancer Center NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that a late-breaking abstract with preliminary findings from the Phase 2 investigator-sponso
Source: finance.yahoo.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer - 2 month(s) ago
AbstractPurpose:. Pancreatic ductal adenocarcinoma (PDAC) trials have evaluated CTLA-4 and/or PD-(L)1 blockade in patients with advanced disease in which bulky tumor burden and limited time to develop antitumor T cells may have contributed to poor clinical efficacy. Here, we evaluated peripheral blood and tumor T cells from patients with PDAC receiving neoadjuvant chemoradiation plus anti–PD-1 (pembrolizumab) versus chemoradiation alone. We analyzed whether PD-1 blockade successfully reactivated T cells in the blood and/or tumor to determine whether lack of clinical benefit could be explained by lack of reactivated T cells versus other factors.Experimental Design:. We used single-cell transcriptional profiling and TCR clonotype tracking to identify TCR clonotypes from blood that match clonotypes in the tumor.Results:. PD-1 blockade increases the flux of TCR clonotypes entering cell cycle and induces an IFNγ signature like that seen in patients with other GI malignancies who respond to
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet-
RT @CCR_AACR: Neoadjuvant PD-1 in PDAC activates T cells nonproductively. https://t.co/nkVNV6CpNb https://t.co/teIzv9CbuJ
-
-
Mashup Score: 35Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C | NEJM - 5 month(s) ago
Original Article from The New England Journal of Medicine — Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
Source: www.nejm.orgCategories: General Medicine News, Oncologists1Tweet-
RT @mgfakih: Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C | NEJM https://t.co/7UYbrWNhc2 Presidentia…
-
-
Mashup Score: 52Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer - 6 month(s) ago
Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer − FRUZAQLA Plus Best Supportive Care Demonstrated Significant Improvements in Overall Survival, with Corresponding Improvements in Progression Free Survival, Versus Placebo Plus Best Supportive Care in Two Phase 3 Clinical Trials Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved FRUZAQLA™ (fruquintinib), an oral targeted therapy for
Source: www.morningstar.comCategories: General Medicine News, Hem/OncsTweet-
RT @CathyEngMD: I am ECSTATIC!!! @US_FDA Approved for 3rd line or greater for #colorectal #cancer https://t.co/sxjzwX6T59 @TakedaOncology @…
-
-
Mashup Score: 48Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer - 6 month(s) ago
Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer − FRUZAQLA Plus Best Supportive Care Demonstrated Significant Improvements in Overall Survival, with Corresponding Improvements in Progression Free Survival, Versus Placebo Plus Best Supportive Care in Two Phase 3 Clinical Trials Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved FRUZAQLA™ (fruquintinib), an oral targeted therapy for
Source: www.morningstar.comCategories: General Medicine News, Hem/OncsTweet-
RT @CathyEngMD: I am ECSTATIC!!! @US_FDA Approved for 3rd line or greater for #colorectal #cancer https://t.co/sxjzwX6T59 @TakedaOncology @…
-
-
Mashup Score: 32Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C | NEJM - 6 month(s) ago
Original Article from The New England Journal of Medicine — Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
Source: www.nejm.orgCategories: General Medicine News, Oncologists1Tweet-
RT @mgfakih: Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C | NEJM https://t.co/7UYbrWNhc2 Presidentia…
-
-
Mashup Score: 1Engineered bacteria detect tumor DNA - 9 month(s) ago
Bacteria can be engineered to detect human DNA with specific mutations, including ones associated with tumors.
Source: www.science.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @weldeiry: Engineered bacteria detect tumor DNA https://t.co/bIJA9bBMav
-
-
Mashup Score: 0Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04) - 10 month(s) ago
AbstractPurpose:. Devimistat (CPI-613) is a novel inhibitor of tumoral mitochondrial metabolism. We investigated the effect of devimistat in vitro and in a phase Ib clinical trial in patients with advanced biliary tract cancer (BTC).Patients and Methods:. Cell viability assays of devimistat ± gemcitabine and cisplatin (GC) were performed and the effect of devimistat on mitochondrial respiration…
Categories: Hem/Oncs, Latest HeadlinesTweet-
RT @CCR_AACR: Devimistat in biliary cancer. https://t.co/dHYY4utvGH https://t.co/aeO94xjOE8
-
-
Mashup Score: 6
GM-CSF-secreting whole-cell cancer vaccine (GVAX) promotes T-cell response against a range of tumor associated antigens in patients with pancreatic adenocarcinoma (PDA). Here the authors report the results of the initial three treatment arms of a platform trial of neoadjuvant and adjuvant GVAX alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable…
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
Out in @NatureComms from the @hopkinskimmel team: A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable #PancreaticCancer @DrLizJaffee https://t.co/3A0RkAGZqK
-
RT @HeumannThatcher: 🔥off the press➡️ https://t.co/oKeZdBjgZk. Immune+clinical outcomes for the first 3 arms of the ongoing platform trial…
-
-
Mashup Score: 2Advances in Precision Medicine Propel Personalized GI Cancer Care - 11 month(s) ago
Eileen O’Reilly, MD, and Benjamin Weinberg, MD, discuss the importance of conducting biomarker testing as the gastrointestinal cancer treatment arena continues to evolve, the need for increased gene fusion testing, and the negative effects of inadequate biomarker testing in the gastrointestinal cancer population.
Source: OncLiveCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @RueschCenter: Advances in Precision Medicine Propel Personalized GI Cancer Care https://t.co/igCpz6SFJB via @onclive @benweinbergmd a…
-
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting https://t.co/eNHCswWFKI